Paper Details

  1. Home
  2. Paper Details

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Author: AmadoriSergio, BeksacMeral, BernemanZwi, BronDominique, CameraAndrea, CantoreNicola, CilloniDaniela, FabbianoFrancesco, FaziPaola, FilletGeorges, GuimaraesJose E, HagemeijerAnne, HalkesConstantijn J M, JansenJoop, LabarBoris, LefrèreFrancois, LeoniPietro, LuppiMario, MagroDomenico, ManciniMarco, MandelliFranco, MarieJean-Pierre, MarijtErik W A, MeertLiv, MelilloLorella, MeloniGiovanna, MistrikMartin, MitraMaria E, MuusPetra, NobileFrancesco, SborgiaMarco, SelleslagDominik L D, SicaSimona, SpecchiaGiorgina, SuciuStefan, ThomasXavier, TrisoliniSilvia M, VendittiAdriano, VignettiMarco, WillemzeRoelof, de WitteTheo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized controlled trial compared standard-dose (SD) cytarabine with high-dose (HD) cytarabine in the treatment of newly diagnosed patients with acute myeloid leukemia (AML). The study found that HD cytarabine produced higher remission and survival rates than SD cytarabine, especially in patients younger than age 46 years.
Paper Details　
Original Abstract of the Article :
PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2013.51.8571

データ提供：米国国立医学図書館（NLM）

High-Dose Cytarabine: A Game Changer in AML Treatment?

The treatment of acute myeloid leukemia ([AML]), a serious blood cancer, is a complex and evolving field. This study focuses on the effectiveness of high-dose cytarabine, a chemotherapy drug, in AML treatment. Researchers [conducted a randomized trial] involving over 1,900 patients with AML, comparing the outcomes of standard-dose and high-dose cytarabine treatment regimens. Their findings provide valuable insights into the potential benefits of high-dose cytarabine, particularly for younger patients.

High-Dose Cytarabine: A Beacon of Hope for Younger Patients

The study's findings suggest that high-dose cytarabine is associated with improved survival rates, particularly for patients younger than 46 years old. This finding is significant as it highlights the potential of high-dose cytarabine to significantly impact the course of AML treatment, especially in this younger patient population.

Navigating AML Treatment: A Guide to the Desert

AML is a complex disease, and the best course of treatment will vary depending on individual factors such as age, overall health, and the specific type of AML. For younger patients with AML, the findings of this study suggest that high-dose cytarabine may be a valuable treatment option. However, it is important to consult with a qualified healthcare professional to discuss all available treatment options and make informed decisions about the best course of action.

Dr. Camel's Conclusion

The study, like a seasoned camel guide leading a caravan through the desert, unveils the potential of high-dose cytarabine as a powerful tool in the fight against AML. The findings highlight the importance of personalized treatment approaches tailored to the specific needs of each patient. As research continues to shed light on the complexities of AML, the insights gained from this study offer hope for improved treatment strategies and a brighter future for those affected by this disease.
Date :
  1. Date Completed 2014-03-17
  2. Date Revised 2014-01-20
Further Info :

Pubmed ID

24297940

DOI: Digital Object Identifier

10.1200/JCO.2013.51.8571

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.